Novo Nordisk freezes hiring amid cost-cutting measures and pressure from obesity drug rivals.

Novo Nordisk has implemented a global hiring freeze for non-business-critical roles to rein in costs amid pressure from copycat versions of its obesity treatment Wegovy and main rival Eli Lilly. The move comes after a profit warning that erased $70 billion from its market value. CEO Mike Doustdar has stated he will pursue cost savings and consider layoffs.

Novo Nordisk, a leading pharmaceutical company, has announced a global hiring freeze for non-business-critical roles in response to escalating costs and market pressures. The move comes following a significant market value drop and a revised sales growth projection, highlighting the company's strategic efforts to stabilize its financial position.

The hiring freeze, confirmed by the company, is a cost-cutting measure under the leadership of newly appointed CEO Maziar Mike Doustdar. This decision reflects Novo Nordisk's urgent response to a series of challenges, including rising competition from copycat GLP-1 drugs and a 42% stock decline. The company's U.S. GLP-1 market share has fallen to 43%, trailing behind Eli Lilly's Zepbound, which holds 57% of the market [1].

Novo Nordisk's financial resilience is under scrutiny. Despite a 25% year-over-year increase in operating profit and a 22% rise in net profit during the first half of 2025, the company's cash flow from financial activities has been volatile. A 343% year-over-year spike in Q2 2025 to -$6.2 billion, and a 62.5% decline in 12-month totals to -$8.3 billion, underscore the financial strain [1].

The hiring freeze and potential layoffs aim to reduce labor costs but risk slowing innovation. Novo's pipeline includes promising candidates like CagriSema and oral amycretin, but the termination of eight R&D projects signals a shift toward short-term cost discipline. While this may stabilize near-term cash flow, it could weaken the company's ability to out-innovate rivals like Eli Lilly [1].

Investors remain cautious, with a "Hold" consensus rating, as Novo Nordisk balances short-term cost discipline against long-term R&D needs and regulatory challenges. The stock, trading at ~DKK 325.90, has fallen 42% year-to-date, mirroring broader investor anxiety [1].

Novo Nordisk's strategic implications for investors include accelerating the approval of CagriSema and oral semaglutide, mitigating compounded drug threats through legal action and regulatory advocacy, and rebalancing cost-cutting with R&D investment to avoid stifling innovation [1].

The hiring freeze is a necessary but insufficient step for Novo Nordisk to regain dominance. For now, a cautious "Hold" remains prudent, with a focus on execution risks and the pipeline's ability to reestablish the company as a leader in obesity care.

References:
[1] https://www.ainvest.com/news/novo-nordisk-hiring-freeze-strategic-cost-control-early-warning-eroding-market-dominance-2508/